FK463

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

NeutropeniaCandidiasisAspergillosis

124 competitors in Neutropenia

#DrugCompanyPhaseTrials

1

Cubicin

BBaxter Healthcare Corporation

Phase 3

32

Mycostatin

GGood Molecules, LLC

Phase 3

13

Caspofungin Acetate

Merck & Co.

Phase 3

44

Amphotericin B Deoxycholate

Merck & Co.

Phase 3

15

Liposomal Lurtotecan

Gilead

Phase 3

16

Alcohol

Astellas

Phase 3

—7

Medrol

Pfizer

Phase 2

18

G-CSF

AArog Pharmaceuticals, Inc.

Phase 3

39

Jardiance

Boehringer Ingelheim

Phase 2

310

Kineret

SSwedish Orphan Biovitrum

Phase 2

2Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Marrow Transplant1 trial

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001937·800 enrolled

Candidiasis1 trial

Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis

Completed·Astellas·Phase 2·NCT00036179·75 enrolled

Aspergillosis1 trial

Study of FK463 for the Treatment of Invasive Aspergillosis

Completed·Astellas·Phase 2·NCT00036166·326 enrolled

Neutropenia1 trial

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001790·120 enrolled

Details

Drug Info

Related News